The first patients have been dosed in Moderna's Phase III clinical trial of its mRNA vaccine candidate to protect against COVID-19.
List view / Grid view
Filter the results
Catalent's biologics facility will conduct large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate.
Sterile and antiviral packaging: unlocking the potential of business continuity and resilience during COVID-19 pandemic
Amid the disruptions due to COVID-19, companies providing sterile and antiviral packaging solutions look forward to opportunities arising from the concern over viral exposure itself. Regulatory compliance will play a significant role in the rapidly shifting risk terrain.
Catalent believes it is essential to share knowledge and experience to improve understanding of drug formulation and delivery challenges and contribute jointly to finding solutions. Will Downie, Senior Vice President, Global Sales and Marketing at Catalent, explains how his company makes a success of this strategy...
European Pharmaceutical Review has brought you the most up-to-date and relevant pharmaceutical science for the past 21 years. This anniversary supplement brings you a selection of topical views from across the industry, reviewing progress over that time, as well as looking to the future.
During 2002, the United States Food and Drug Administration (FDA) requested rationalisation and modernisation of the manufacturing base for pharmaceutical production. This was in the hope that modernising the supply chain would enhance the robustness of manufacturing processes, thereby reducing product failures and, importantly, significantly enhancing product quality.1 The FDA’s…
Catalent & Sanofi to collaborate on SMARTag™ antibody-drug conjugate technology with Sanofi’s proprietary antibodies
16 January 2015 | By Catalent
Catalent Pharma Solutions has entered into a collaboration with Sanofi-Aventis Recherche & Développement, a Sanofi Company to implement Catalent’s proprietary SMARTag™ technology in the development of next generation Antibody-Drug Conjugates...
19 February 2014 | By Paul Wituschek, Vice President of Sales, Development and Clinical Services, Catalent
Paul Wituschek, Vice President of Sales, Development and Clinical Services, Catalent answers the question: "Other than oncology, for which disease areas do you see Antibody Drug Conjugates (ADC) being used extensively in the future?"
10 July 2013 | By Catalent Pharma Solutions
Catalent Pharma Solutions has entered into a contract with Biota Pharmaceuticals, Inc...
Catalent announces major China expansion with two new facilities for Softgel Technologies and Clinical Supply Solutions businesses
11 March 2013 | By Catalent Pharma Solutions
Catalent announced two joint ventures...
Catalent Applied Drug Delivery Institute launches 2nd annual Global Academic Competition for Life Sciences Leaders of Tomorrow
30 January 2013 | By Catalent Pharma Solutions
Aim to encourage students...